Murphy Middleton Hinkle & Parker’s Pfizer PFE Stock Holding History

Murphy Middleton Hinkle & Parker’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$797K	Sell	33,101 -89	-0.3%	-$2.33K	0.32%	78
2026 Q1	$932K	Buy	+33,190	New	+$884K	0.43%	67
2025 Q4	–	Sell	-33,453	Closed	-$852K	–	205
2025 Q3	$852K	Sell	33,453 -1,563	-4%	-$38.6K	0.42%	69
2025 Q2	$887K	Hold	35,016	–	–	0.5%	61
2025 Q1	$887K	Sell	35,016 -2,642	-7%	-$69.1K	0.5%	61
2024 Q4	$999K	Sell	37,658 -1,561	-4%	-$42.3K	0.56%	56
2024 Q3	$1.14M	Sell	39,219 -912	-2%	-$26.6K	0.61%	51
2024 Q2	$1.12M	Sell	40,131 -820	-2%	-$22.6K	0.65%	48
2024 Q1	$1.14M	Sell	40,951 -1,211	-3%	-$33.6K	0.66%	48
2023 Q4	$1.21M	Sell	42,162 -5,252	-11%	-$159K	0.75%	41
2023 Q3	$1.57M	Buy	47,414 +811	+2%	+$28.7K	1.01%	30
2023 Q2	$1.71M	Sell	46,603 -1,466	-3%	-$57.1K	1.07%	30
2023 Q1	$1.96M	Buy	48,069 +4	+0%	+$173	1.22%	28
2022 Q4	$2.46M	Sell	48,065 -424	-0.9%	-$20.3K	1.55%	21
2022 Q3	$2.12M	Buy	48,489 +1,200	+3%	+$58.3K	1.48%	23
2022 Q2	$2.48M	Buy	47,289 +721	+2%	+$36.7K	1.61%	19
2022 Q1	$2.41M	Sell	46,568 -883	-2%	-$45.8K	1.29%	23
2021 Q4	$2.8M	Sell	47,451 -874	-2%	-$43.3K	1.49%	18
2021 Q3	$2.08M	Buy	48,325 +323	+0.7%	+$14.3K	1.2%	27
2021 Q2	$1.88M	Sell	48,002 -614	-1%	-$23.9K	1.05%	32
2021 Q1	$1.76M	Sell	48,616 -927	-2%	-$32.9K	1.03%	35
2020 Q4	$1.82M	Sell	49,543 -2,778	-5%	-$102K	1.22%	27
2020 Q3	$1.82M	Sell	52,321 -2,499	-5%	-$87.6K	1.33%	22
2020 Q2	$1.7M	Buy	54,820 +1,035	+2%	+$35.2K	1.25%	24
2020 Q1	$1.67M	Buy	53,785 +277	+0.5%	+$9.44K	1.47%	23
2019 Q4	$1.99M	Buy	53,508 +6	+0%	+$214	1.32%	26
2019 Q3	$1.82M	Sell	53,502 -169	-0.3%	-$6.14K	1.29%	26
2019 Q2	$2.21M	Sell	53,671 -964	-2%	-$38.3K	1.57%	20
2019 Q1	$2.2M	Sell	54,635 -156	-0.3%	-$6.25K	1.51%	20
2018 Q4	$2.27M	Sell	54,791 -2,385	-4%	-$99K	1.73%	17
2018 Q3	$2.39M	Buy	57,176 +4	+0%	+$154	1.69%	14
2018 Q2	$1.97M	Buy	57,172 +6	+0%	+$205	1.47%	20
2018 Q1	$1.93M	Sell	57,166 -848	-1%	-$29.2K	1.5%	22
2017 Q4	$1.99M	Buy	+58,014	New	+$1.98M	1.48%	23

Other funds holding PFE

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

ORIO

Old Republic International (ORI) Chicago, Illinois $2.67B AUM 26.94% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Kepler Cheuvreux Nyon $1.75B AUM 37.37% 1-Year Est. Return

Murphy Middleton Hinkle & Parker's PFE Position: Q2 2026 in Review

Murphy Middleton Hinkle & Parker reduced its Pfizer (PFE) stake by 0.27% in Q2 2026, selling an estimated $2.33K and leaving 33,101 shares worth $797K. The position accounts for 0.32% of the portfolio, ranked #78.

Murphy Middleton Hinkle & Parker first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.8M in Q4 2021. 588 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Murphy Middleton Hinkle & Parker held 33,101 shares of Pfizer worth $797K as of Q2 2026.
Murphy Middleton Hinkle & Parker sold 89 Pfizer shares in Q2 2026, an estimated $2.33K.
Pfizer made up 0.32% of Murphy Middleton Hinkle & Parker's portfolio in Q2 2026, its #78 holding.
Murphy Middleton Hinkle & Parker first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
Murphy Middleton Hinkle & Parker's Pfizer position peaked at $2.8M in Q4 2021.
588 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Murphy Middleton Hinkle & Parker's 13F filing for Q2 2026, filed 14 Jul 2026.